Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study

Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study

Background: EN-DEAVOR was a multi-institutional retrospective study evaluating the effectiveness and safety of trastuzumab deruxtecan (T-DXd) in gastric cancer patients. This secondary analysis investigated prognostic factors for real-world progression-free survival (rwPFS) and objective response ra...

Full description

Saved in:
Bibliographic Details
Main Authors: K. Nakanishi, N. Sugimoto, Y. Kodera, H. Kawakami, A. Makiyama, H. Konishi, S. Morita, Y. Narita, K. Minashi, M. Imano, R. Inamoto, T. Nishina, T. Kawakami, M. Hagiwara, H. Kume, K. Yamaguchi, W. Hashimoto, K. Muro
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:ESMO Gastrointestinal Oncology
Subjects:
EN-DEAVOR
gastric or gastroesophageal junction cancer
HER2 positive
prognostic factors
trastuzumab deruxtecan
modified Glasgow Prognostic Score
Online Access:http://www.sciencedirect.com/science/article/pii/S2949819825000536
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2949819825000536

Similar Items